United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal's angina [see warnings and precautions (5.1) ] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway d

United States - English - NLM (National Library of Medicine)

orchidpharma, inc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets, reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] - history of stroke

United States - English - NLM (National Library of Medicine)

paddock laboratories, llc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg

United States - English - NLM (National Library of Medicine)

sandoz inc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use: naratriptan is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women. data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [see data]. in animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. the lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (mrdd) [see data]. in the u.s. genera

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. limitations of use: naratriptan is contraindicated in patients with: risk summary: there are no adequate data on the developmental risk associated with use of naratriptan in pregnant women. data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [see data]. in animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. the lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (mrdd) [see data]. in the u.s. general popul

United States - English - NLM (National Library of Medicine)

glaxosmithkline llc - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 1 mg - amerge is indicated for the acute treatment of migraine with or without aura in adults. limitations of use amerge is contraindicated in patients with: risk summary there are no adequate data on the developmental risk associated with use of amerge in pregnant women. data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [see data] . in animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. the lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (mrdd) [see data] . in the u.s. general population, the estimated bac

United States - English - NLM (National Library of Medicine)

bionpharma inc. - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. limitations of use - use only if a clear diagnosis of migraine has been established. if a patient has no response to the first migraine attack treated with naratriptan tablets, reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. - naratriptan tablets are not indicated for the prevention of migraine attacks. - safety and effectiveness of naratriptan tablets have not been established for cluster headache. naratriptan tablets are contraindicated in patients with: - ischemic coronary artery disease (cad) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including prinzmetal’s angina [see warnings and precautions (5.1)] - wolff-parkinson-white syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see warnings and precautions (5.2)] - history of stroke or transient ischemic attack (tia) or history of hemiplegic or basilar migraine because such patients are at a higher risk of stroke [s ee warnings and precautions (5.4)] - peripheral vascular disease [see warnings and precautions (5.5)] - ischemic bowel disease [see warnings and precautions (5.5)] - uncontrolled hypertension [see warnings and precautions (5.8)] - recent use (i.e., within 24 hours) of another 5-ht1 agonist, ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide) [see drug interactions (7.1, 7.2)] - hypersensitivity to naratriptan tablets (angioedema and anaphylaxis seen) [see warnings and precautions (5.9)] - severe renal or hepatic impairment [see use in specific populations (8.6, 8.7), clinical pharmacology (12.3)] risk summary there are no adequate data on the developmental risk associated with use of naratriptan tablets in pregnant women. data from a prospective pregnancy exposure registry and epidemiological studies of pregnant women have documented outcomes in women exposed to naratriptan during pregnancy; however, due to small sample sizes, no definitive conclusions can be drawn regarding the risk of birth defects following exposure to naratriptan [see data] . in animal studies, naratriptan produced developmental toxicity (including embryolethality and fetal abnormalities) when administered to pregnant rats and rabbits. the lowest doses producing evidence of developmental toxicity in animals were associated with plasma exposures 2.5 (rabbit) to 11 (rat) times that in humans at the maximum recommended daily dose (mrdd) [see data] . in the u.s. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. the reported rate of major birth defects among deliveries to women with migraine ranged from 2.2% to 2.9% and of miscarriage was 17%, which were similar to rates reported in women without migraine. clinical considerations disease-associated maternal and/or embryo/fetal risk several studies have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy. data human data : the numbers of exposed pregnancy outcomes accumulated during the sumatriptan/naratriptan/treximet® (sumatriptan and naproxen sodium) pregnancy registry, a population-based international prospective study that collected data from october 1997 to september 2012, and smaller observational studies, were insufficient to define a level of risk for naratriptan in pregnant women. the registry documented outcomes of 57 infants and fetuses exposed to naratriptan during pregnancy (52 exposed during the first trimester and 5 exposed during the second trimester). the occurrence of major birth defects (excluding fetal deaths and induced abortions without reported defects and all spontaneous pregnancy losses) during first-trimester exposure to naratriptan was 2.2% (1/46 [95% ci: 0.1% to 13%]) and during any trimester of exposure was 2% (1/51 [95% ci: 0.1% to 11.8%]). seven infants were exposed to both naratriptan and sumatriptan in utero, and one of these infants with first-trimester exposure was born with a major birth defect (ventricular septal defect). the sample size in this study had 80% power to detect at least a 3.8 to 4.6 fold increase in the rate of major malformations. in a study using data from the swedish medical birth register, women who used triptans or ergots during pregnancy were compared with women who did not. of the 22 births with first-trimester exposure to naratriptan, one infant was born with a malformation (congenital deformity of the hand). animal data : when naratriptan was administered to pregnant rats during the period of organogenesis at doses of 10, 60, or 340 mg/kg/day, there was a dose-related increase in embryonic death; incidences of fetal structural variations (incomplete/irregular ossification of skull bones, sternebrae, ribs) were increased at all doses. the maternal plasma exposures (auc) at these doses were approximately 11, 70, and 470 times the exposure in humans at the mrdd. the high dose was maternally toxic, as evidenced by decreased maternal body weight gain during gestation. a no-effect dose for developmental toxicity in rats exposed during organogenesis was not established. when naratriptan was administered orally (1, 5, or 30 mg/kg/day) to pregnant dutch rabbits throughout organogenesis, the incidence of a specific fetal skeletal malformation (fused sternebrae) was increased at the high dose, the incidence of fetal variations (major blood vessel variations, supernumerary ribs, incomplete skeletal ossification) was increased at the mid and high doses, and embryonic death was increased at all doses (4, 20, and 120 times, respectively, the mrdd on a body surface area basis). maternal toxicity (decreased body weight gain) was evident at the high dose. in a similar study in new zealand white rabbits (1, 5, or 30 mg/kg/day throughout organogenesis), decreased fetal weights and increased incidences of fetal skeletal variations were observed at all doses (maternal exposures equivalent to 2.5, 19, and 140 times exposure in humans receiving the mrdd), while maternal body weight gain was reduced at 5 mg/kg or greater. a no-effect dose for developmental toxicity in rabbits exposed during organogenesis was not established. when female rats were treated orally with naratriptan (10, 60, or 340 mg/kg/day) during late gestation and lactation, offspring behavioral impairment (tremors) and decreased offspring viability and growth were observed at doses of 60 mg/kg or greater, while maternal toxicity occurred only at the highest dose. maternal exposures at the no-effect dose for developmental effects in this study were approximately 11 times the exposure in humans receiving the mrdd. risk summary there are no data on the presence of naratriptan in human milk, the effects of naratriptan on the breastfed infant, or the effects of naratriptan on milk production. naratriptan is present in rat milk. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for naratriptan tablets and any potential adverse effects on the breastfed infant from naratriptan or from the underlying maternal condition. safety and effectiveness in pediatric patients have not been established. therefore, naratriptan tablets are not recommended for use in patients younger than 18 years of age. one controlled clinical trial evaluated naratriptan tablets (0.25 to 2.5 mg) in 300 adolescent migraineurs aged 12 to 17 years who received at least 1 dose of naratriptan tablets for an acute migraine. in this study, 54% of the patients were female and 89% were caucasian. there were no statistically significant differences between any of the treatment groups. the headache response rates at 4 hours (n) were 65% (n = 74), 67% (n = 78), and 64% (n = 70) for placebo, 1 mg, and 2.5 mg groups, respectively. this trial did not establish the efficacy of naratriptan tablets compared with placebo in the treatment of migraine in adolescents. adverse reactions observed in this clinical trial were similar in nature to those reported in clinical trials in adults. clinical trials of naratriptan tablets did not include sufficient numbers of patients aged 65 and older to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. naratriptan is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in elderly patients who have reduced renal function. in addition, elderly patients are more likely to have decreased hepatic function, they are at higher risk for cad, and blood pressure increases may be more pronounced in the elderly. a cardiovascular evaluation is recommended for geriatric patients who have other cardiovascular risk factors (e.g., diabetes, hypertension, smoking, obesity, strong family history of cad) prior to receiving naratriptan tablets [see warnings and precautions (5.1)]. the use of naratriptan tablets are contraindicated in patients with severe renal impairment (creatinine clearance: <15 ml/min) because of decreased clearance of the drug. in patients with mild to moderate renal impairment, the recommended starting dose is 1 mg, and the maximum daily dose should not exceed 2.5 mg over a 24 hour period [see dosage and administration (2.2), clinical pharmacology (12.3)]. the use of naratriptan tablets are contraindicated in patients with severe hepatic impairment (child-pugh grade c) because of decreased clearance. in patients with mild or moderate hepatic impairment (child-pugh grade a or b), the recommended starting dose is 1 mg, and the maximum daily dose should not exceed 2.5 mg over a 24 hour period [see dosage and administration (2.3), clinical pharmacology (12.3)].

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries limited - naratriptan hydrochloride (unii: 10x8x4p12z) (naratriptan - unii:qx3kxl1za2) - naratriptan 2.5 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - naratriptan hydrochloride - oral tablet - 2.5mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - naratriptan hydrochloride - oral tablet - 2.5mg